Clinical trials: Inadequate Response
Rheumatoid Arthritis
Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis
A 12-week with possible extension, phase II study to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day in combination with methotrexate, in treatment of patients with active rheumatoid arthritis refractory to standard…
- Trial name
- NCT00913432
- Testing
- masitinib
- Volunteers
- 20 people
- Sponsor
- AB Science
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage
This randomized, placebo-controlled, double-blind study will compare the safety and efficacy of tapering methotrexate (MTX) versus maintaining MTX dosage in patients with severe active rheumatoid arthritis and an inadequate…
- Trial name
- NCT01661140
- Testing
- Methotrexate (stable dose), Tocilizumab, Methotrexate (tapering dose)
- Where
- 67 sites in United Kingdom
- Volunteers
- 427 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
The purpose of this study is to assess Abatacept Intravenous (IV) effectiveness in patients with inadequate response to one or more conventional Disease Modifying Against Rheumatism (DMARDs) including Methotrexate in France…
- Trial name
- ReACTION (NCT02037737)
- Testing
- Abatacept
- Volunteers
- 153 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)
Brief Summary: This is a randomized, double-blind study comparing LNK01001 to placebo in Chinese participants with moderately to severely active rheumatoid arthritis who are on a stable dose of conventional synthetic…
- Trial name
- NCT06276998
- Testing
- LNK01001
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Major Depression Disorder
Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment
The purpose of this study is to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in an elderly population with major depressive disorder and an inadequate response to antidepressant treatment
- Trial name
- NCT02400346
- Testing
- Adjunct brexpiprazole, ADT
- Where
- 34 sites in United States, Estonia and 3 more
- Volunteers
- 132 people
- Sponsor
- H. Lundbeck A/S
Psoriasis
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
This multicenter, prospective, observational, single-arm, 26-week study will evaluate the effectiveness, safety and tolerability of brodalumab subcutaneous injection in participants with psoriasis with inadequate response to…
- Trial name
- NCT04149587
- Testing
- Brodalumab
- Where
- 11 sites in Canada
- Volunteers
- 252 people
- Sponsor
- Bausch Health Americas, Inc.
Arthritis, Rheumatoid
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 6 dose regimens of CP-690,550, combined with methotrexate, for the treatment of adults with active rheumatoid arthritis.
- Trial name
- NCT00413660
- Testing
- CP-690,550
- Where
- 82 sites in United States, Argentina and 11 more
- Volunteers
- 509 people
- Sponsor
- Pfizer
Acute Decompensated Heart Failure
DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
The study objective is to observe and measure clinical outcomes, urine output, and safety events occurring during standard medical treatment of ADHF patients deemed to have insufficient diuretic response.
- Trial name
- NCT04877652
- Testing
- Standard of care
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Revamp Medical Ltd.
Rheumatoid Arthritis
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
Primary Objective: To assess the effect of sarilumab in combination with conventional synthetic Disease-Modifying Anti-Rheumatic Drug (csDMARD) and/or monotherapy on participant-reported impact of disease, using the rheumatoid…
- Trial name
- SariPRO (NCT03449758)
- Testing
- SARILUMAB, Azathioprine, Chloroquine
- Where
- 33 sites in France
- Volunteers
- 84 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking methotrexate but not responding.
- Trial name
- OSKIRA - 1 (NCT01197521)
- Testing
- fostamatinib
- Where
- 127 sites in United States, Argentina and 15 more
- Volunteers
- 923 people
- Sponsor
- AstraZeneca
Ulcerative Colitis
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).
- Trial name
- U-ASTOUND (NCT05782907)
- Testing
- Upadacitinib
- Where
- 89 sites in United States, Australia and 21 more
- Volunteers
- 122 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
This observational, prospective, multicenter study will evaluate the efficacy and safety of MabThera/Rituxan in participants with active rheumatoid arthritis and an inadequate response or intolerance to one anti-TNF therapy.
- Trial name
- NCT01641952
- Testing
- Rituximab
- Where
- Romania
- Volunteers
- 505 people
- Sponsor
- Hoffmann-La Roche
Major Depressive Disorder
Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
To evaluate the efficacy and safety of brexpiprazole as adjunctive treatment in elderly patients with Major Depressive Disorder (MDD)
- Trial name
- NCT01837797
- Testing
- Brexpiprazole 1 mg, Brexpiprazole 3 mg
- Where
- 2 sites in United States
- Volunteers
- 129 people
- Sponsor
- H. Lundbeck A/S
Rheumatoid Arthritis
Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA)
Rheumatoid Arthritis (RA) is a systemic inflammatory autoimmune disorder that leads to inflammation and progressive joint damage affecting 2.5 million people in the United States.
- Trial name
- NCT00796705
- Testing
- Adalimumab, Etanercept
- Where
- 16 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Active Polyarticular Juvenile Idiopathic Arthritis
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
The purpose of this study is to estimate Abatacept steady-state trough concentration (Cmin) at Day 113 in children and adolescents with pJIA
- Trial name
- NCT01844518
- Testing
- Abatacept
- Where
- 57 sites in United States, Argentina and 10 more
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune and chronic inflammatory disease that causes progressive damage to joints of the body, affecting the functional capacity.
- Trial name
- TERRA (NCT01430507)
- Testing
- Revamilast
- Where
- 36 sites in India, Philippines and 3 more
- Volunteers
- 406 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- REASSURE (NCT01377012)
- Testing
- Secukinumab (AIN457)
- Where
- 142 sites in United States, Argentina and 14 more
- Volunteers
- 637 people
- Sponsor
- Novartis Pharmaceuticals
Primary Biliary Cholangitis
Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC
Study to evaluate the efficacy, safety, and tolerability of investigational drug obeticholic acid (OCA) in combination with the investigational drug bezafibrate (BZF) in participants with Primary Biliary Cholangitis (PBC).
- Trial name
- NCT04594694
- Testing
- Obeticholic acid, Bezafibrate 200 MG, Bezafibrate 400 MG
- Where
- 33 sites in Australia, Belgium and 15 more
- Volunteers
- 75 people
- Sponsor
- Intercept Pharmaceuticals
Rheumatoid Arthritis
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNF Therapy (REPEAT)
This observational study will assess the efficacy and safety of MabThera/Rituxan (Rituximab) in patients with active rheumatoid arthritis who have had an inadequate response or are intolerant to anti-TNF therapy.
- Trial name
- NCT01196780
- Where
- Romania
- Volunteers
- 1,240 people
- Sponsor
- Hoffmann-La Roche